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Introduction
Transforming Growth Factor b (Tgfb) isoforms 1, 2, and 3 are the eponymous members of the Tgfb superfamily that comprises more than 40 different cytokines. Although several specific functions are attributable to each of the isoforms in vivo, very likely caused by specific expression of one isoform in a specific cellular context, Tgfb1, 2, and 3 are homologous proteins and probably replaceable in vitro. Thus, for convention, in this study, we will refer to the term ''Tgfb'' whenever exogenous Tgfb was used (normally TGFb1, unless otherwise indicated) or when we will refer to all 3 isoforms. For in vivo studies, the specific isoform used or manipulated is indicated.
Tgfb has versatile functions both between and within different organ systems. This also holds true for the nervous system, in which overexpression of Tgfb1 in mice results in hydrocephalus and gliogenesis (Wyss-Coray et al. 1995) , treatment of dopaminergic neurons with Tgfb causes either neurotoxic degeneration or neurotrophic effects (Krieglstein and Unsicker 1994; Krieglstein et al. 1995; Commissiong et al. 1997; Sanchez-Capelo et al. 1999; Farkas et al. 2003) , and in which Tgfb can induce ontogenetic cell death (Krieglstein et al. 2000) . Thus, to unravel Tgfb functions in the nervous system, it is necessary to analyze its actions with respect to different cell populations and even to different developmental stages. In this study, we aimed to understand the function of Tgfb during forebrain development because little is known about the role of this multifunctional cytokine in this biological context.
Tgfb and corresponding receptors are expressed in the forebrain: Tgfb2 and Tgfb3 are found in progenitors, differentiating neurons and radial glial cells, whereas Tgfb1 is expressed mainly in mesenchymal cells of meninges and choroid plexus during development (Flanders et al. 1991; Miller 2003; Falk et al. 2008 ). Tgfb upregulates cell cycle inhibitors, mainly p21, and counteracts cell cycle progression of cortical neuroepithelial cells of E10.5 mouse brains and of E17.5 rat cortical slice cultures (Seoane et al. 2004; Siegenthaler and Miller 2005) . Inactivation of Tgfb receptor II in the forebrain through Emx1-cre does not alter neuroepithelial proliferation at E12.5 and lacks a cortical phenotype at E18.5 (Falk et al. 2008 ). However, Tgfb1 inactivation leads to a compacted and thinner neocortex accompanied by increased apoptosis in neonatal and adult mice, indicating that Tgfb1 functions in survival of central nervous system (CNS) neurons (Brionne et al. 2003) .
Further insight into Tgfb function in the CNS comes from studies of the midbrain, which is also influenced by Tgfb. Here, dorsal progenitors are vulnerable to the loss of Wnt1-cre--induced conditional loss of Tgfb receptor II, leading to increased cell proliferation and self-renewal of neuroepithelial cells in vivo and in vitro (Falk et al. 2008) . In these animals, ventral midbrain progenitors are not affected, although ventral dopaminergic neurons and progenitors respond to Tgfb signaling. In chicken, Tgfb is involved in differentiation of a dopaminergic phenotype (Farkas et al. 2003) , and Tgfb neutralization results in selective loss of ventrally located dopaminergic neurons. Mouse E12.5 ventral midbrain--derived neurospheres express dopaminergic markers TH and Nurr1 upon exposure to Tgfb. Furthermore, dopaminergic differentiation into a TH-and Nurr1-positive phenotype is also promoted when dorsal E12.5 midbrain is used for generating neurospheres (Roussa et al. 2006) . In this context of dopaminergic neuron development, Tgfb increases differentiation but does not influence proliferation of progenitors (Roussa et al. 2006) .
Several data corroborate the finding that Tgfb exerts antimitogenic functions on early neuronal progenitors through activation of p21, which interferes with G1 progression and entry into the S phase. Thus, although the idea that Tgfb might influence the production of neurons or glial cells from forebrain progenitors seems likely, it has actually not been proven so far. And it is conceivable that inhibition of p21 is only the start, after which further cellular events are initiated and influenced through Tgfb. To unravel Tgfb functions during forebrain development, we studied the effect of this multifunctional cytokine on cortical and hippocampal cultures and on possible target genes. This study shows, for the first time, that Tgfb not only mediates exit from the cell cycle but also promotes adoption of a neuronal cell fate in vitro and in vivo. This process is dependent upon Smad signaling and induction of integrin-signaling protein Nedd9/Hef1.
Materials and Methods

Primary Cultures of Mouse Embryonic Hippocampal and Cortical Cells
All experiments were performed according to national and international guidelines on the ethical use of animals.
Hippocampal and cortical cells were isolated from embryonic mice at E16.5 or 14.5, dissected in Hanks' Balanced Salt Solutions (Gibco, Karlsruhe, Germany) and dissociated by trypsinization in 0.25% Trypsin--ethylenediaminetetraacetic acid (Gibco) at 37°C for 8 min followed by gentle trituration. Cells were plated on poly-L-ornithin (0.1 mg/mL, Sigma, Mu¨nchen, Germany) and laminin (1 lg/mL, Sigma) coated dishes at a density of 150 000 cells/cm 2 and cultured in Neurobasal-medium (Gibco) supplemented with B27 (Gibco), apo-transferrin (5 lg/mL, Sigma), glutathione (1 lg/mL, Sigma), superoxide-dismutase (0.8 lg/mL, Sigma), and glutamine (0.5 mM, Gibco). After 4 days in vitro (DIV), half of the medium was changed every 3 days.
Immunocytochemistry
Tgfb2/Tgfb3 mutant mice were generated as described (Roussa et al. 2006) . Cryosections were processed with microwaving for 7 min twice in 0.01 M citrate buffer and subsequent blockage of endogenous peroxidases for Diaminobenzidine (DAB)-based staining. Primary antibodies NeuN (mouse, 1:150, Millipore) and Ki67 (rabbit, 1:100, Epitomics) were applied overnight and detected with DAB-based staining (Ki67) or donkey antimouse Cy3 (NeuN). In the latter, red fluorescence image was converted to black and white using Photoshop. Only the red channel in the channels palette was activated and inverted under image-adjustments-invert.
For quantification of marker proteins, 0.8 3 10 5 (hippocampus) or 1 3 10 5 (cortex) cells were plated on poly-L-ornithin/laminin precoated 12-mm glass coverslips. For most experiments, TGFb1 (5 ng/mL, Peprotech, London, United Kingdom) or ALK4,5,7-Inhibitor SB431542 (10 lM, Biozol, Eching, Germany) was added to the medium on DIV2 at a concentration of 5 ng/mL and replaced with each medium exchange. TGFb2 and TGFb3 (Peprotech) were used under the same conditions. Before analysis, cells were fixed in 4% PFA for 10 min, blocked 30 min in 10% normal goat or donkey serum, 0.1% Triton X-100 in PBS, and incubated overnight at 4°C with primary antibody in blocking solution, followed by the corresponding secondary antibody for 1 h at room temperature in PBS. Primary antibodies used were 5-Bromo-2-deoxyuridine (BrdU; sheep, 1:500, Abcam), Doublecortin (goat, 1:100, Santa Cruz Biotechnology), Pax6 (rabbit, 1:300, Covance), Nestin (rabbit, 1:500, Abcam), GFAP (mouse, 1:500, Sigma), HuC/D (mouse, 1:100, Invitrogen), Ki67 (rat, 1:25, Dako), HEF1 (NEDD9, mouse, 1:500, Abcam), PSA Ncam (mouse, 1:20, Developmental Studies Hybridoma Bank), and Smad 1,2,3 (mouse, 1:100, Santa Cruz Biotechnology). Secondary antibodies used were donkey antimouse, antirabbit, or antisheep Cy3 (1:800); goat antimouse, antirabbit FITC (1:100); and donkey antirat FITC (1:100) (all Jackson ImmunoResearch, West Grove, PA). Cell bodies were counterstained with DAPI (1:1000, Sigma), coverslips mounted with Fluoromount-G (Southern Biotechnology, Birmingham, AL) and visualized with an Axio Imager Z1 microscope (Zeiss, Jena, Germany). Quantification was performed by counting 10 random fields from 2 slides per experimental set. Data were collected from at least 3 independent experiments and are represented as mean ± standard error of mean (SEM). To verify whether differences between TGFb1 treatment and untreated control reached the significance level P < 0.05, student's t-tests were used.
Smad Nuclear Translocation Assay
Hippocampal cells seeded on coverslips were preincubated with ALK4,5,7-Inhibitor SB431542 (10 lM) for 24 h to suppress endogenous TGFb signaling. Then, cells were washed twice and stimulated with TGFb1 (5 ng/mL) for 1 h. After fixation, cells were stained with mouse anti-Smad 1,2,3 (1:100, Santa Cruz Biotechnology, Santa Cruz, CA).
TGFb Secretion Assay
For detection of active and latent Tgfb released in the culture medium by cortical and hippocampal cells, the mink lung epithelial cell (MLEC) luciferase bioassay was used as described (Abe et al. 1994; Krieglstein et al. 2000) .
BrdU Labeling
Cells were plated on coverslips and stimulated with TGFb1 until fixation at DIV8. Twenty-four hours prior to fixation, 20 nM BrdU (Sigma) was added to the medium. Fixed cells were incubated in 1 N HCl for 10 min on ice followed by an incubation for 20 min in 2 N HCl at 37°C, neutralization in 0.1 M borate buffer and blocking in 5% normal donkey serum, 1% Triton X-100 in PBS, and incubation with sheep-anti-BrdU (1:500, Abcam, Cambridge, United Kingdom) overnight at 4°C. The number of BrdU-positive cells and the total number of cells were counted. For determination of the quitting fraction (QF), cells were treated with TGFb1 from DIV2 onward. BrdU was added for 24 h prior to fixation at DIV4. Cells were processed for immunocytochemistry and double labeled with anti-BrdU and anti-Ki67. All BrdUpositive cells either positive or negative for Ki67 were counted.
FACS Analysis of Apoptotic Cell Death
Hippocampal and cortical cells were treated with 5 ng/mL TGFb1 starting at DIV2. At DIV4 or DIV8, cells were trypsinized, fixed with 70% ethanol in PBS, and stored at -20°C for at least 2 h. Directly before analysis, DNA was stained with propidium iodide by resuspending the cells in fluorescence activated cell sorting (FACS) buffer containing 100 lg/mL propidium iodide, 10 lg/mL RNAse in PBS for 30 min at 37°C. Data are expressed as percentage of cells present in the sub-G1 peak, representing apoptotic cells.
RNA Isolation and RT-PCR
For Tgfb target gene expression analyses, cells were preincubated with ALK4,5,7-Inhibitor SB431542 (10 lM) for 24 h to decrease endogenous Tgfb signaling, washed twice, and stimulated with 5 ng/mL TGFb1 for 2 or 24 h. Expression of Tgfb isoforms and receptors was assessed from untreated control cells.
Total RNA was isolated at DIV4 or DIV12 using the RNeasy Kit (Qiagen) according to the manufacturer's instructions. First-strand cDNA was synthesized from 1 lg of total RNA with RevertAid MMuLV reverse transcriptase (Fermentas) using oligo(dT) primers (Invitrogen). One microliter of the RT reaction mixture was subjected to PCR amplification.
Quantitative real-time RT-PCR analysis was performed on an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA), using SYBR Green PCR Master Mix (Applied Biosystems) in a MicroAmp 96-well reaction plate following the manufacturer's protocols. Gapdh was used as a reference to obtain the relative fold change for target samples using the comparative CT method. Primer sequences are shown in supplemental data table S1.
Lentivirus-Delivered RNA Interference All shRNA containing lentiviral transduction particles were purchased from Sigma (Mission shRNA). One or 2 constructs for each gene with more than 85% knockdown efficiency were used. For control infection, nontarget shRNA control was used. Cortical and hippocampal cells were infected with the viruses at DIV2 for 48 h and then subjected to selection by 0.8 lg/mL puromycin for 24 h prior to TGFb1 treatment. Sequences used in the shRNA vectors are shown in supplemental data table S2.
Statistics
Data are presented as the mean ± SEM. Statistical analysis was performed using 2-tailed unpaired Student's t-test for in vitro data and 1-tailed unpaired Student's t-test for evaluation of in vivo results. Differences were considered statistically significant at *P < 0.05, **P < 0.01, and ***P < 0.001.
Results
Primary Cortical and Hippocampal Cultures Secrete Tgfb and Activate Tgfb-Dependent Smad-Signaling Pathways To determine whether Tgfb signaling is necessary for proper development of neurons, we used cultures of primary cortical and hippocampal neurons isolated from E14.5 and E16.5 mouse embryonic brains. Under the applied cell culture conditions, primary neurons of both origins produced Tgfb in its active or inactive, protein-bound latent form over several DIV (Fig. 1A and data not shown). In vivo studies show that different Tgfb isoforms are active in specific parts of the brain during development, for example, Tgfb1 is mainly produced by mesenchymal cells of meninges and choroid plexus, whereas Tgfb2 and Tgfb3 are produced in neural cells (Flanders et al. 1991; Pelton et al. 1991) . In vitro, cortical and hippocampal cells produced all 3 Tgfb isoforms, as well as their main receptors mediating signal transduction (Fig. 1B) . Thus, primary neuronal cells in culture are endogenously exposed to Tgfb indicating that this cytokine might play an important role in neuronal development and function. Furthermore, these data imply that loss-of-function studies focussing on Tgfb ligands 1, 2, and 3 would require a knockdown of all 3 isoforms. To circumvent this difficulty, we decided to study Tgfb effects primarily using exogenous supplementation.
To prove that supply of exogenous Tgfb would result in the activation of downstream signaling, we analyzed Smad phosphorylation and translocation into the nucleus. Endogenous Tgfb signaling also activated Smad signaling, and this background activity hampered direct investigation of Smad phosphorylation and translocation after exongenous supply of Tgfb. We therefore exposed neuronal cultures for 24 h to the Alk4,5,7 inhibitor SB431542 to block endogenous Tgfb signaling and subsequently replaced the inhibitor with 5 ng/ mL TGFb1. Using these conditions, we were able to observe increased Smad phosphorylation (data not shown) and translocation (Fig. 1C) . Taken together, these data showed that primary neuronal cultures not only produced all 3 Tgfb isoforms but also expressed the respective Tgfb receptors and activated Smad signaling. Expression of all these different components of Tgfb signal transduction machinery therefore raised the question whether Tgfb would influence cellular processes such as proliferation, apoptosis, or differentiation.
Tgfb Reduces Progenitor Proliferation and Favors Differentiation into Neurons
Tgfb signaling is context dependent and involved in diverse cellular processes affecting different cell populations. Such cellular processes include proliferation, apoptosis, and differentiation. We therefore analyzed the effect of Tgfb on embryonal hippocampal and cortical cells with regard to these cellular processes.
Accordingly, quantitative analyses of the proliferative cell population in hippocampal cultures after 8 DIV and 6 days of Tgfb treatment revealed about 12% less Ki67-or BrdUpositive progenitors compared with untreated cultures (Fig. 2A) . About 7% less Ki67-or BrdU-positive cells were counted in cortical cultures after Tgfb treatment compared with untreated control samples ( Fig. 2A) . This finding was corroborated by the observation that Tgfb treatment for 48 h at DIV2 resulted in a smaller cycling fraction (CF = (BrdU + ;Ki67 + )/(BrdU + )) and a higher quitting fraction (QF = (BrdU + ;Ki67 -)/(BrdU + )) in hippocampal and cortical cells (Fig. 2B) . Because Tgfb is also implicated in apoptotic processes, we used propidium iodide--based FACS analyses of Tgfb-treated samples to test for increased apoptosis that might have led to a loss of progenitor cells. We did not observe enhanced apoptosis in hippocampal and cortical cultures that were exposed either short-term (DIV4) or longer-term (DIV8) to Tgfb (Fig. 2C) . To confirm this finding, we counted TUNELpositive cells and confirmed that Tgfb did not promote cell death under the applied conditions (data not shown).
Taken together, these observations showed for the first time that exposure to Tgfb resulted in an antiproliferative response of progenitor cells in hippocampal cultures and corroborated earlier studies of cortical progenitors.
Because we also determined a higher fraction of cells that were exiting the cell cycle (Fig. 2B ) after Tgfb treatment, we next investigated whether exposure to Tgfb would result in an increase of differentiated cells, for example, neurons or glia. We visualized neurons using HuC/D and NeuN, neural progenitors using Nestin and Pax6, and glial cells using GFAP (Fig. 3A) . Quantitative analyses revealed that Tgfb treated cultures contained 17% more neurons in cortical, and 20% more neurons in hippocampal cultures, but less neuronal progenitors, for example, 12% less Nestin-and 5% less Pax6-expressing cortical cells, and 9% less Nestin-positive cells in hippocampal cultures, respectively. The number of GFAP-positive glial cells was unaffected by Tgfb (Fig. 3B,C) .
These experiments were all performed with TGFb1. In vivo, Tgfb1 is mainly expressed in mesenchymal cells, and Tgfb2 and Tgfb 3 are active in CNS-derived cells, whereas all 3 isoforms are expressed in vitro (Fig. 1B) . Thus, we also analyzed whether the observed effect mediated through TGFb1 was also seen when using the other 2 isoforms. Indeed, we observed that TGFb2 and TGFb 3 were also capable of increasing the number of neurons (Fig. 3D) .
To investigate whether the length of Tgfb treatment would be of critical influence, we exposed cells for 24 h at DIV2 to Tgfb and analyzed the number of neurons at DIV8. Distribution of HuC/D-positive neurons indicated that the 24 h Tgfb pulse was sufficient to increase the number of neurons (Fig. 3E) . Next, we analyzed whether the time point of starting Tgfb treatment would be important by exposing cultures at DIV5 to Tgfb for 3 days, and counting HuC/D-positive cells at DIV8. Under these conditions, we observed only a slight increase in neurons (7%) (Fig. 3E) . We therefore hypothesized that Tgfb is capable of initiating neuronal differentiation at DIV2 and DIV5 but that the differences observed were due to a shorter time period during which differentiation would have had time to progress (6 and 3 days, respectively). Indeed, Tgfb treatment for 48 h at DIV2 and analysis at DIV4 did not result in more HuC/D-positive cells, reflecting a critical time period that is necessary for the differentiating neurons to express the respective markers (data not shown). Cultures treated at DIV5 for 24 h or 6 days, and analyzed for HuC/D at DIV11, contained again up to 20% more neurons than untreated cells (Fig. 3E) . Thus, Tgfb was capable of promoting a neuronal cell fate at DIV2 and DIV5 in similar ratios when cultures were analyzed after a 6-day differentiation interval. However, Tgfb treatment produced fewer differentiated neurons in older cultures treated at DIV8 up to DIV14 (Fig. 3E ). This might reflect that older cultures generally contained more neurons and fewer progenitors under the conditions in B27 medium, which supports differentiation.
In summary, neuronal progenitors are competent to generate neurons upon exposure to Tgfb over the entire culture period, where upon a minimal time frame of 2--3 days is necessary to detect changes in the expression of differentiation markers.
To further investigate the association of this neurogenic effect with a functional Tgfb signaling pathway, we treated cells with Tgfb together with the Alk4,5,7-inhibitor SB431542, which blocks Tgfb receptor I kinase activity, and observed a block in the increase in HuC/D positive cells (Fig. 3F) . We next investigated whether the neurogenic effect of Tgfb was dependent upon Smad signaling, using a lentivirus expressing a Smad4 shRNA (validation shown in supplementary fig. 1 ) that was transduced in cortical and hippocampal cells at DIV2. We did not observe an increase in neurons after Tgfb treatment when we interfered with Smad-pathway activity. Rather, we observed that neurons were generated in similar numbers as in transduced but non-Tgfb exposed control cells (Fig. 3G,H) , suggesting that Tgfb activation of the Smadsignaling pathway is a central component of Tgfb-mediated neuronal differentiation. Hippocampal and cortical cultures were treated for 6 days with TGFb, labeled with BrdU (20 nM) in the last 24 h, and stained for BrdU and Ki67, detecting decreased numbers of proliferating progenitors (n 5 3), P values: ***P \ 0.001, **P \ 0.01, student's t-test. (B) Determination of cells leaving the cell cycle within the first 48 h of TGFb exposure. Treatment started at DIV2; after 24 h, BrdU was added and after another 24 h, cells were fixed and costained for BrdU and Ki67. BrdU incorporation had not changed at this time point, but there was an increase in the number of cells quitting the cell cycle (QF) and a corresponding decrease of cells that reenter the cell cycle (CF) (all n 5 3), P values: ***P \ 0.001, **P \ 0.01, student's t-test. (C) PI-FACS analysis of apoptotic cells after short-time (DIV2--DIV4) and long-time (DIV2--DIV8) treatment with TGFb (n 5 3).
In summary, these data showed for the first time that Tgfb not only had antiproliferative functions on hippocampal and cortical progenitors but also that Tgfb treatment introduced a bias toward differentiation into neurons, which was dependent on a functional Tgfb/Smad-signaling pathway.
Tgfb2/Tgfb3 Mutant Mice Display Fewer Neurons and Increased Progenitor Proliferation
To confirm our finding that Tgfb signaling interferes with cell cycle progression and promotes neuronal differentiation in hippocampal and cortical primary cultures in vivo, we analyzed Tgfb2 -/-/Tgfb3 -/-double mutant forebrains. Because these mutations are lethal by E15.5 (Dunker and Krieglstein 2002), we used E14.5 mutants for analyzing expression of Ki67 and NeuN. As shown in Figure 4 , NeuN staining revealed that a loss of Tgfb signaling resulted in fewer neurons in the cerebral cortex (Fig. 4A,B) , as well as in the hippocampus (Fig. 4C,D) . The quantification of these observations is shown in Figure 4I . Loss of Tgfb2 and Tgfb3 signaling resulted also in increased cell proliferation in the cerebral cortex (Fig. 4F ) and in the hippocampus (Fig. 4H ) compared with control littermates Influence of the duration of the TGFb pulse and the age of the cultures on the TGFb-induced neurogenetic effect in hippocampal cultures. A short TGFb pulse of 24 h was sufficient to enhance neuronal differentiation (2,5,7) in the same way as a long pulse of 6 days over the entire cultivation period (1,4,6). TGFb was also able to promote a neuronal cell fate in older cultures from DIV5 (4,5) at a similar rate as in cultures from DIV2 (1,2). In cultures where TGFb treatment was started on DIV8 (6,7) ( Fig. 4E,G,J) . Taken together, these in vivo data clearly corroborated our findings in primary cell cultures of the hippocampus and cerebral cortex.
Tgfb-Mediated Neuronal Differentiation is Associated with Cell Cycle Exit and Induction of Integrin-Associated Protein Nedd9
Tgfb controls cell cycle progression at the G1/S checkpoint (Urano et al. 1999; Hu and Zuckerman 2001) and it has been recognized that Tgfb exerts antiproliferative effects during cortical development (Siegenthaler and Miller 2005) . As expected, genes associated with cell cycle progression were also regulated in hippocampal cultures upon exposure to Tgfb. Specifically, RT-PCR from cells that were exposed to Tgfb for 2 h revealed that p21 and p57 expression was induced, whereas a 24-h Tgfb treatment resulted in downregulation of p21, p57, Ccnd1, and Ccnd2 in E16.5 hippocampal cells cultured for 4DIV (Fig. 5A) . The Cdk inhibitors p21 and p57, and the Cdk activators Ccnd1 and Ccnd2 converge in the regulation of cell progression through G1 phase and the ratio of p21 to CyclinD--Cdk complexes determines Cdk activity where high ratios of Cdk inhibitors to CyclinD--Cdk complexes suppress Cdk activation and interfere with G1 progression (Sherr 1995) . Thus, induction of p21 and downregulation of Ccnd1 and Ccnd2 through Tgfb likely prevented neuronal progenitors from progressing through G1 and entering the S phase.
However, induction of cell cycle inhibitors might be a prerequisite for entering differentiation but may not be sufficient to generate neurons. Because it is unknown whether inhibition of cell cycle progression is the only function of this multifunctional cytokine in this context, we examined whether the neurogenic capacity of Tgfb is associated with the regulation of further target genes. Several published microarray data (Verrecchia et al. 2001; Zavadil et al. 2001; Ota et al. 2002; Kang et al. 2003; Yang et al. 2003; Zhao et al. 2004) identified Tgfb-regulated genes in non-CNS-derived cells. We therefore based our analyses by screening these published data for genes that might also be relevant for developmental processes of the forebrain. Altogether, we selected 114 genes (supplementary (I) and Ki67 (J) positive cells in the cerebral cortex and hippocampus of age-matched control and Tgfb2/Tgfb3 double mutants (n 5 2, P value: * P \ 0.05, one-tailed student's t-test).
table 1) for investigating Tgfb-dependent regulation in hippocampal and cortical cells. Our data showed that hippocampal and cortical cultures produce Tgfb on their own and thus exhibit autocrine Tgfb signaling. To circumvent this problem, we pretreated the cultures with the Alk4,5,7-inhibitor for 24 h to block endogenous Tgfb signaling and then assessed changes in expression levels of putative target genes. This was done by releasing cells from this block and treating hippocampal cultures for 2 or 24 h with Tgfb at DIV4 (Fig. 5B) and DIV12 (Fig. 5C) . Using semiquantitative and quantitative RT PCR, we identified Tgfb-regulated target genes associated with neuronal differentiation of CNS derived progenitors, including Gata2, Runx1, Nedd9, and Ctgf. These 4 genes were upregulated at least 3-fold in real-time PCR assays and/or were regulated in a Smad4-dependent manner (Fig. 5C) . Therefore, we investigated whether interference with their expression would also interfere with Tgfb-associated neuronal cell fate adoption. We transduced hippocampal cultures with lentiviruses containing shRNAs for Gata2, Runx1, and Nedd9 (validation shown in supplementary fig. 2 ) and investigated hippocampal or cortical cells that were generated from Ctgf knockout mice (Ivkovic et al. 2003) . As shown in Figure 5D and E, downregulation of Gata2 and Runx1 did not interfere with Tgfb-mediated neuronal differentiation. In contrast, downregulation of Nedd9 prevented increased neuronal differentiation after exposure to Tgfb (Fig. 5F ), indicating that this focal adhesion protein, known to be involved in integrin signaling, is part of the molecular machinery that promotes the adoption of a neuronal cell fate. Loss of Ctgf did not affect the capacity of Tgfb to generate more neurons in hippocampal or cortical cultures (Fig. 5G,H) .
Tgfb Treatment Alters the Morphology of Nestin-Positive Progenitors
In the course of our experiments, we observed that Tgfb not only depleted the pool of neuronal progenitors, but immunocytochemical analyses also revealed that the morphology of this proliferative pool of cells changed as well (Fig. 6 ). Nestin is a marker of multipotential precursors, and Nestin-positive cells were found in clusters in our cultures. These clusters contained cells with a large round nucleus and a large cell body without processes, as well as several cells with a smaller nucleus and cell body with short processes. Treatment with Tgfb not only reduced the overall number of Nestin clusters (data not shown), but it also increased the number of cells with small cell bodies and processes at the expense of the larger, rounder cells. In contrast, treatment with the Tgfb-inhibitor SB431542 favored the larger, rounder phenotype, and small cells with processes were rarely found (Fig. 6) . Costaining with Ki67 revealed that although Tgfb induced striking morphological changes of Nestin-positive progenitors, this subpopulation of cells still proliferated (Fig. 6A ). This finding suggested that (Fig. 6B,C) . A minor fraction of cells displayed colocalized expression of GFAP and Nestin (Fig. 6B) , observable in Tgfb-treated and control cells, encompassing untreated as well as Tgfb-inhibitor (SB431542) treated cells. PSA-NCam did not colocalize with Nestin in control cells, but Tgfb-treated cells showed partial coexpression (Fig. 6C ). No colocalization with Nestin was found in Dcx-expressing cells under control and Tgfb-induced conditions (Fig. 6D) . These findings suggested that the Tgfb-induced morphological change did not correlate with a lineage commitment, but that these cells retain their uncommitted precursor status. We identified Nedd9 as an essential downstream component of Tgfb-mediated neuronal differentiation. Additionally, Nedd9 has been described as a molecule involved in changes of cell morphology (Singh et al. 2007) , and that is expressed in multipotent Nestin-positive cells in vivo (Aquino et al. 2008) . We therefore investigated whether the observed Tgfbdependent morphological changes correlated with the expression of Nedd9 in Nestin-positive progenitors. As shown in Figure 6E , most of the Nestin-positive cells did not express Nedd9 or expressed Nedd9 only at a low level under both control conditions. In Tgfb-treated samples, Nestin-positive cells displayed a higher degree of colocalization with Nedd9, and nearly all cell bodies of progenitors with Nestin-positive processes stained positive for Nedd9. Thus, Nedd9 is expressed in a subset of Nestin-positive cells albeit at a low level, and exposure to Tgfb induced a higher proportion of Nedd9--Nestin double-positive progenitors. However, although these findings render Nedd9 as a candidate target that might be involved in the morphological changes of progenitor cells induced by Tgfb, additional studies with Nedd9 mutant mice will be necessary to prove this hypothesis.
Discussion
In this study, we have shown that forebrain-derived embryonic progenitor cells are responsive to Tgfb, which introduces a shift in differentiation into the neuronal but not into the glial cell lineage. Thus, Tgfb not only promotes cell cycle exit but also activates pathways leading to neuronal differentiation, a process that depends upon the activation of Smad signaling and the induction of the focal adhesion protein Nedd9.
Our study was focussed on cortical and hippocampal cells that were cultured in vitro and our findings extend earlier reports that Tgfb influences the developing cerebral cortex. Using slice cultures of E17.5 rat cerebral cortices, Siegenthaler and Miller (2005) showed that Tgfb1 promotes cell cycle exit through induction of p21. We now provide evidence that Tgfb also influences hippocampal cells and not only induces exit from the cell cycle, but that Tgfb also leads to a decrease of progenitors and increasing numbers of neurons in the developing hippocampus as well as in the cerebral cortex.
The observed neurogenic potential of Tgfb signaling was confirmed in vivo using Tgfb2
-/-double mutants. This is the first Tgfb-related mouse model in which enhanced cell proliferation and impaired neuronal differentiation has been shown in the forebrain.
Tgfb1 knockout mice, which survive to early adulthood, have a thinner cerebral cortex. This mutant displayed higher rates of apoptosis in cortical Tgfb1 -/-neurons, which was considered to be the main cause for loss of neurons (Brionne et al. 2003) . Our data now provide evidence that defects in neuronal differentiation during development might also have contributed to the observed loss of neurons. Interestingly, survival of neurons in our cultures also depended upon Tgfb signal transduction, because we observed higher rates of apoptosis when we blocked the TgfbRI with the inhibitor SB431542 over several days (data not shown).
Other published mouse mutants in which Tgfb signaling is hampered do not develop an observable phenotype in the forebrain, as is the case for many TgfbRII conditional mutants (our own unpublished data, and Falk et al. 2008 ). In the latter, one reason for a lack of an observable phenotype might be that restricting the knockout to a subset of cells using cre-expressing mice may not have the same effect as a complete knockout of the 2 major Tgfb ligands that are expressed in neurons and progenitors (Flanders et al. 1991) . Another possibility might be that loss of Tgfb signaling is accompanied with an increase of progenitor proliferation. Because neuronal differentiation is not solely dependent on Tgfb signaling, it might be sufficient if more precursors are generated, which subsequently differentiate. This higher number of differentiating precursors might compensate for the loss of the Tgfb-mediated differentiation signal during the entire course of development.
Further support for our finding that Tgfb signaling is involved in neuronal differentiation comes from studies on the development of dopaminergic neurons. Here, midbrainderived E12.5 progenitors differentiated into dopaminergic neurons upon exposure to Tgfb in vitro, and this developmental process was as significantly impaired in E14.5 Tgfb2/Tgfb3 double mutants (Roussa et al. 2006) .
That Tgfb influences progenitors not only through cell cycle exit is corroborated by our observation of morphological changes of Nestin-positive progenitors. These multipotent cells nevertheless continue proliferating and do not show any signs of early lineage restriction after Tgfb treatment. Furthermore, apart from cell cycle control genes, we identified other components that are regulated through Tgfb signaling in hippocampal and cortical cultures, 4 of which were tested for their implication in Tgfb-mediated neuronal differentiation. Although Ctgf, Runx1, and Gata2 are not involved in this process, siRNA-mediated downregulation of Nedd9 abolished the neurogenic potential of the Tgfb signaling pathway.
Nedd9 (Neural precursor cell expressed, developmentally downregulated 9), which was initially identified in embryonic brains, is downregulated during developmental progression (Kumar et al. 1992 ) and enriched in neural progenitor cells (Abramova et al. 2005) . Further studies identified Nedd9 in Nestin-and Sox2-positive progenitors in the neuroepithelium, and its downregulation is linked to neuronal lineage commitment (Aquino et al. 2008) . Furthermore, Nedd9 variation is associated with susceptibility of late-onset Alzheimer's disease and Parkinson's disease (Chapuis et al. 2008; Li et al. 2008) .
Nedd9, also known as Hef1 or Cas-L, is a scaffolding protein that is implicated in b1-integrin-signal transduction because it is localized at focal adhesions and associates with focal adhesion kinase upon b1-integrin ligation. Like Tgfb, it is implicated in diverse biological processes including cell attachment, migration, and invasion, as well as apoptosis and cell cycle regulation (reviewed in Singh et al. 2007) . Little is known about Nedd9 function in the nervous system. Our study shows for the first time that Nedd9 is implicated in Tgfbmediated differentiation into the neuronal lineage. Taken together with its expression pattern, our data suggest that Nedd9 might promote a progenitor status that renders the cells competent to differentiation into neurons.
Several studies describe an association of Tgfb-signaling and Nedd9 activity, although not in the nervous system. In human dermal fibroblasts, TGFb1 upregulates Nedd9 mRNA and protein levels but does not change posttranslational modifications, for example, phosphorylation of Nedd9 (Zheng and McKeown-Longo 2002) . Furthermore, Nedd9 potentiates Tgfb signaling by relieving negative feedback by the inhibitory Smads 6 and 7 (Inamoto et al. 2007 ). Smad3 also interacts with Nedd9, which can lead to proteasomal degradation of the latter after Tgfb exposure and therefore facilitates Smad3-mediated nuclear responses. However, sustained Tgfb signaling leads to increased levels of Nedd9, which binds Smad3 and negatively regulates Smad3-dependent Tgfb signaling (Liu et al. 2000; Nourry et al. 2004) . Such pathways might promote differentiation of specific progenitors as has been shown during spinal cord development (Garcia-Campmany and Marti 2007) and might also take place during forebrain development.
Taken together, our data provide new findings on the role of Tgfb on hippocampal as well as cortical cells and highlight a role for Nedd9 in neuronal differentiation. These data will be the basis for extended studies to enlighten the function of Nedd9 in different CNS-derived progenitor populations and with respect to different developmental time points.
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